ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
05/04/201608:00:00Merck to Present at the Deutsche Bank 41st Annual Health Care...
05/03/201603:05:00Gilead Seeks to Tame Merck Case -- WSJ
05/02/201619:57:00Judge Allows More Evidence in Patent Dispute After Gilead Says...
05/02/201617:51:00Judge Allows More Evidence in Patent Dispute After Gilead Says...
05/02/201616:50:00Judge Allows More Evidence in Gilead-Merck Patent Dispute
05/02/201616:37:00Judge Allows More Evidence in Patent Dispute After Gilead Says...
04/28/201618:11:00Gilead Reports Drop in Hepatitis C Drug Revenue -- Update
04/28/201617:00:00Gilead Reports Drop in Hepatitis C Drug Revenue
04/28/201608:50:00AbbVie Agrees to Buy Stemcentrx, Reports Jump in Earnings
04/28/201608:00:00Christina Applegate and Merck Urge Insomnia Sufferers to Learn...
04/27/201608:00:00Merck, the American Diabetes Association and America's Diabetes...
04/27/201601:00:00Journal of the American Medical Association Publishes Phase III...
04/26/201611:39:00Journal of the American Medical Association Publishes Phase III...
04/26/201604:10:00Bayer Posts 13% Jump in Net Profit
04/19/201617:00:00Merck Animal Health to Acquire Worldwide Rights to Whisper®...
04/19/201614:05:00Merck Statement on Blueprint Project Findings Presented at the...
04/18/201608:00:00Merck Receives Breakthrough Therapy Designation from U.S. Food...
04/17/201620:50:00Bristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial
04/16/201601:00:00Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir...
04/14/201614:52:55Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad